HighGravityData

Intuitive Surgical

Guidance from Intuitive Surgical’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
4 items
Releases tracked
8
Latest release
Jul 16, 2026
Data checked
Jul 16, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Jul 16, 2026 release

Each item compared with the same item in the previous release (Apr 21, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
RaisedNon-GAAP gross profit marginfor FY2026“within a range of 67.5% and 68.5% of revenue”“68.0% to 69.0% of revenue”Filing ↗
NarrowedNon-GAAP operating expense growthfor FY2026“11% to 14%”“11% to 13%”Filing ↗
ReiteratedWorldwide da Vinci procedure growthfor FY2026“approximately 13.5% to 15.5%”“approximately 13.5% to 15.5%”Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Estimated impact from tariffs on non-GAAP gross profit margin“1.0% of revenue”for FY2026Company-definedApr 21, 20261Filing ↗
Non-GAAP gross profit margin“68.0% to 69.0% of revenue”for FY2026Company-definedApr 21, 20262Filing ↗
Non-GAAP operating expense growth“11% to 13%”for FY2026Company-definedApr 21, 20262Filing ↗
Worldwide da Vinci procedure growth“approximately 13.5% to 15.5%”for FY2026Company-definedJan 14, 20263Filing ↗

How one item moved

Worldwide da Vinci procedure growth, for FY2025 — every statement across the year, each linked to its filing.

Jan 15, 2025
New
“approximately 13% to 16%”
Apr 22, 2025
Raised
“approximately 15% to 17%”
Jul 22, 2025
Narrowed
“approximately 15.5% to 17%”
Oct 21, 2025
Raised
“approximately 17% to 17.5%”

How your Medical devices & equipment sector group guides

12 companies in Medical devices & equipment. What they guide on, and who reported this season.

Most-guided metric families
Revenue
9
Organic growth
8
Adjusted EPS
8
Buybacks
6
GAAP EPS
5
Operating margin
4
Dividends
3
Gross margin
2
This season’s releases
MedtronicSep 1, 20263 changes
Becton DickinsonAug 6, 20264 changes
ResMedAug 6, 20260 changes
InsuletAug 5, 202625 changes
Zimmer BiometAug 5, 20263 changes
DexComJul 30, 20263 changes
StrykerJul 30, 20262 changes
Boston ScientificJul 29, 20265 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2026FY2025
Estimated impact from tariffs on non-GAAP gross profit margin1 statement2 statements
Estimated tariff impact included in non-GAAP* gross profit margin range—1 statement
Non-GAAP gross profit margin2 statements3 statements
Non-GAAP operating expense growth2 statements3 statements
Worldwide da Vinci procedure growth3 statements4 statements
The full record for Intuitive Surgical and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Jul 16, 2026FY2026 Q20001035267-26-0000473Open filing ↗
Apr 21, 2026FY2026 Q10001035267-26-0000294Open filing ↗
Jan 14, 2026FY2025 Q40001035267-26-0000031Open filing ↗
Oct 21, 2025FY2025 Q30001035267-25-0002064Open filing ↗
Jul 22, 2025FY2025 Q20001035267-25-0001834Open filing ↗
Apr 22, 2025FY2025 Q10001035267-25-0001064Open filing ↗
Jan 15, 2025FY2024 Q40001035267-25-0000051Open filing ↗
Oct 17, 2024FY2024 Q30001035267-24-0002440Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error